Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_db8acd71f5994544bda6df3f27a3f51e |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-24234 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55544 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-295 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-29 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-861 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-295 |
filingDate |
2016-07-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0c6306bc2aa6128b874b3a1be055dcd6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6c76beaa1860d29d43ebd6df43070c36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d8606762d0177390a6b18fbdad1f643f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3de9980de8ad50451417aaca233d5d02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_69756ae34bd8005b7d3e2c064e6e4f8f |
publicationDate |
2017-01-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
WO-2017006182-A1 |
titleOfInvention |
Hepatitis c virus immunogenic compositions and methods of use thereof |
abstract |
The present disclosure provides heterodimeric polypeptides comprising: 1) a variant hepatitis C virus (HCV) E2 polypeptide and an HCV El polypeptide; 2) a variant HCV El polypeptide and an HCV E2 polypeptide; or 3) a variant HCV El polypeptide and a variant HCV E2 polypeptide, where the variant HCV E2 polypeptide and/or the HCV El polypeptide comprises one or more T cell epitopes, present in an HCV polypeptide other than an HCV El polypeptide or an HCV E2 polypeptide. The present disclosure provides nucleic acids encoding a polyprotein that includes El and variant E2, E2 and variant El, or variant E2 and variant El. The present disclosure provides a method of producing an E1/E2 heterodimer of the present disclosure. The present disclosure provides a method of inducing an immune response in an individual. The present disclosure provides variant E2 polypeptides and variant E1 polypeptides; and nucleic acids encoding same. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2016336150-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019173925-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3359577-A4 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11596679-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108290960-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108290960-B http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3618859-A4 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11324818-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112601548-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11660332-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018200975-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11186615-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3515483-A4 |
priorityDate |
2015-07-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |